Skip to content
Press Releases
Filter Releases
 
Press Releases
Nov 2, 2016
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $6.00 per share. The gross proceeds to Veracyte from this offering, before deducting underwriting discounts and commissions and o...
PDF
Nov 1, 2016
SOUTH SAN FRANCISCO, Calif., Nov. 1, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that it has commenced an underwritten public offering of its common stock. All of the shares are being offered by Veracyte. In addition, Veracyte expects to grant the underwriters a 30-day option to purchase additional shares of its common stock ...
PDF
Oct 26, 2016
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced new data from a prospective, multicenter clinical utility study showing that use of the Percepta Bronchial Genomic Classifier to resolve inconclusive diagnostic results in patients undergoing evaluation for suspected lung cancer led to a signifi...
PDF
Oct 25, 2016
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced the launch of the Envisia Genomic Classifier at the CHEST Annual Meeting 2016 in Los Angeles. Envisia is expected to be the fir...
PDF
Oct 17, 2016
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today released preliminary unaudited financial results for the third quarter ended September 30, 2016. Third Quarter 2016 Prelimi...
PDF
Oct 13, 2016
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced that external researchers will present data from three studies reinforcing the clinical impact and value of the company's Perce...
PDF
Sep 30, 2016
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing diagnostic uncertainty, today issued the statement below on the Centers for Medicare and Medicaid Services' (CMS) final 2017 "gapfill" Medicare reimbursement rate for the Afirma Gene Expression Classifier (GEC...
PDF
Sep 23, 2016
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced new data suggesting the potential to enhance the performance of the Afirma Gene Expression Classifier in thyroid cancer diagnosis by combining the test's proven RNA expression-based capabilities with gene variant and fusion information - all on...
PDF
Sep 15, 2016
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), has posted a draft local coverage determination (LCD) for the Percepta Bronchial Genomic Classifier. The Palmetto draft LCD posting follows the September 8 posting by Noridian Healt...
PDF
Sep 15, 2016
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that external researchers will present six posters that reinforce the role of the Afirma Gene Expression Classifier (GEC) as a new standard of care in thyroid cancer diagnosis at the 86th Annual Meeting of the American Thyroid Association (ATA)...
PDF
Page: First Previous
...
Next Last